Gavin Giovannoni

5.2k total citations · 1 hit paper
63 papers, 3.7k citations indexed

About

Gavin Giovannoni is a scholar working on Pathology and Forensic Medicine, Oncology and Rheumatology. According to data from OpenAlex, Gavin Giovannoni has authored 63 papers receiving a total of 3.7k indexed citations (citations by other indexed papers that have themselves been cited), including 53 papers in Pathology and Forensic Medicine, 19 papers in Oncology and 18 papers in Rheumatology. Recurrent topics in Gavin Giovannoni's work include Multiple Sclerosis Research Studies (53 papers), Polyomavirus and related diseases (17 papers) and Immunotherapy and Immune Responses (15 papers). Gavin Giovannoni is often cited by papers focused on Multiple Sclerosis Research Studies (53 papers), Polyomavirus and related diseases (17 papers) and Immunotherapy and Immune Responses (15 papers). Gavin Giovannoni collaborates with scholars based in United Kingdom, United States and Germany. Gavin Giovannoni's co-authors include Eva Havrdová, Krzysztof Selmaj, Michael Panzara, Douglas L. Arnold, Alasdair Coles, D. A. S. Compston, David Margolin, J. Theodore Phillips, Jeffrey Cohen and Ralf Gold and has published in prestigious journals such as The Lancet, Neurology and The Lancet Neurology.

In The Last Decade

Gavin Giovannoni

63 papers receiving 3.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial

2012 883 citations Jeffrey Cohen, Alasdair Coles et al. The Lancet profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Gavin Giovannoni United Kingdom	26	3.0k	1.2k	1.1k	944	798	63	3.7k
Martin Toal United States	6	1.9k 0.6×	977 0.8×	600 0.6×	685 0.7×	417 0.5×	9	2.6k
A Wajgt Poland	10	2.5k 0.8×	1.3k 1.0×	828 0.8×	872 0.9×	542 0.7×	37	3.3k
Ludwig Kappos Switzerland	2	1.9k 0.6×	924 0.8×	607 0.6×	660 0.7×	411 0.5×	2	2.5k
Craig H. Smith United States	8	2.4k 0.8×	709 0.6×	1.0k 1.0×	1.6k 1.7×	566 0.7×	12	3.5k
Joachim Burman Sweden	28	1.6k 0.5×	814 0.7×	669 0.6×	686 0.7×	276 0.3×	111	2.8k
Sunil Agarwal United States	10	1.8k 0.6×	471 0.4×	590 0.6×	1.3k 1.4×	1.0k 1.3×	19	3.1k
Bhupendra Khatri United States	17	2.1k 0.7×	670 0.6×	802 0.8×	503 0.5×	425 0.5×	50	2.9k
Kerstin Hellwig Germany	39	2.9k 1.0×	915 0.8×	844 0.8×	1.9k 2.0×	365 0.5×	171	4.2k
Benjamin Brooks United States	9	1.9k 0.6×	451 0.4×	958 0.9×	577 0.6×	653 0.8×	14	2.3k
Emmanuelle Le Page France	18	1.5k 0.5×	551 0.5×	633 0.6×	355 0.4×	389 0.5×	52	1.8k

Countries citing papers authored by Gavin Giovannoni

Since Specialization

Citations

This map shows the geographic impact of Gavin Giovannoni's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gavin Giovannoni with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gavin Giovannoni more than expected).

Fields of papers citing papers by Gavin Giovannoni

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gavin Giovannoni. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gavin Giovannoni. The network helps show where Gavin Giovannoni may publish in the future.

Co-authorship network of co-authors of Gavin Giovannoni

This figure shows the co-authorship network connecting the top 25 collaborators of Gavin Giovannoni. A scholar is included among the top collaborators of Gavin Giovannoni based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gavin Giovannoni. Gavin Giovannoni is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Angelis, Floriana De, Francesca Ammoscato, Richard Parker, et al.. (2025). Neurofilament heavy chain in secondary progressive multiple sclerosis. Multiple Sclerosis Journal. 31(3). 303–313. 1 indexed citations

Giovannoni, Gavin. (2025). Epstein-Barr Virus as a Therapeutic and Preventive Target in Multiple Sclerosis. Current Treatment Options in Neurology. 27(1). 1 indexed citations

Chitnis, Tanuja, Brenda Banwell, Lauren Krupp, et al.. (2020). Temporal profile of lymphocyte counts and relationship with infections with fingolimod therapy in paediatric patients with multiple sclerosis: Results from the PARADIGMS study. Multiple Sclerosis Journal. 27(6). 922–932. 7 indexed citations

Gold, Ralf, Ernst‐Wilhelm Radue, Gavin Giovannoni, et al.. (2020). Long-term safety and efficacy of daclizumab beta in relapsing–remitting multiple sclerosis: 6-year results from the SELECTED open-label extension study. Journal of Neurology. 267(10). 2851–2864. 8 indexed citations

Radue, Ernst W., Till Sprenger, Timothy Vollmer, et al.. (2016). Daclizumab high‐yield process reduced the evolution of new gadolinium‐enhancing lesions to T1 black holes in patients with relapsing−remitting multiple sclerosis. European Journal of Neurology. 23(2). 412–415. 7 indexed citations

Gold, Ralf, Ernst‐Wilhelm Radue, Gavin Giovannoni, et al.. (2016). Safety and efficacy of daclizumab in relapsing-remitting multiple sclerosis: 3-year results from the SELECTED open-label extension study. BMC Neurology. 16(1). 117–117. 39 indexed citations

Havrdová, Eva, Gavin Giovannoni, Douglas L. Arnold, et al.. (2015). Durable Effect of Alemtuzumab on Clinical Outcomes in Patients With Relapsing-Remitting Multiple Sclerosis Who Relapsed on Prior Therapy: 4-Year Follow-up of CARE-MS II (P7.276). Neurology. 84(14_supplement). 3 indexed citations

Kappos, Ludwig, Gavin Giovannoni, Ralf Gold, et al.. (2015). Time course of clinical and neuroradiological effects of delayed‐release dimethyl fumarate in multiple sclerosis. European Journal of Neurology. 22(4). 664–671. 31 indexed citations

LaGanke, Christopher, Regina Berkovich, Jeffrey Cohen, et al.. (2015). Durable Effect of Alemtuzumab on Disability Improvement in Patients With Relapsing-Remitting Multiple Sclerosis Who Relapsed on a Prior Therapy (P3.261). Neurology. 84(14_supplement). 2 indexed citations

10.

Giovannoni, Gavin, Ralf Gold, Robert J. Fox, et al.. (2015). Relapses Requiring Intravenous Steroid Use and Multiple-Sclerosis–related Hospitalizations: Integrated Analysis of the Delayed-release Dimethyl Fumarate Phase III Studies. Clinical Therapeutics. 37(11). 2543–2551. 8 indexed citations

11.

Fox, Edward, Gavin Giovannoni, Douglas L. Arnold, et al.. (2015). Improvement in Clinical Outcomes Following Switch From Subcutaneous Interferon Beta-1a to Alemtuzumab: CARE-MS II Extension Study (P7.278). Neurology. 84(14_supplement). 2 indexed citations

12.

Giovannoni, Gavin, Ralf Gold, Robert J. Fox, et al.. (2013). Relapses Requiring Intravenous Steroid Use and Multiple Sclerosis (MS)-Related Hospitalizations: An Integrated Analysis of the BG-12 (Dimethyl Fumarate) Phase 3 Studies (P07.121). Neurology. 80(7_supplement). 1 indexed citations

13.

Giovannoni, Gavin, Douglas L. Arnold, Jeffrey Cohen, et al.. (2013). Disability Improvement with Alemtuzumab vs. Interferon beta-1a in Relapsing-Remitting Multiple Sclerosis Patients Who Experienced Disease Activity While on Prior Therapy (CARE-MS II) (P07.120). Neurology. 80(7_supplement). 1 indexed citations

14.

Bar‐Or, Amit, Ralf Gold, Ludwig Kappos, et al.. (2013). Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing–remitting multiple sclerosis: subgroup analyses of the DEFINE study. Journal of Neurology. 260(9). 2297–2305. 59 indexed citations

15.

Kappos, Ludwig, Ralf Gold, Douglas L. Arnold, et al.. (2013). Quality of life outcomes with BG-12 (dimethyl fumarate) in patients with relapsing–remitting multiple sclerosis: The DEFINE study. Multiple Sclerosis Journal. 20(2). 243–252. 49 indexed citations

16.

Havrdová, Eva, Ralf Gold, Robert J. Fox, et al.. (2012). PND3 Relapses Requiring Intravenous Steroids and Multiple Sclerosis-Related Hospitalizations: Findings From the Phase 3 Define and Confirm Studies. Value in Health. 15(7). A546–A546. 2 indexed citations

17.

Cohen, Jeffrey, Alasdair Coles, Douglas L. Arnold, et al.. (2012). Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. The Lancet. 380(9856). 1819–1828. 883 indexed citations breakdown →

18.

Giovannoni, Gavin, Eric Southam, & E. Waubant. (2012). Systematic review of disease-modifying therapies to assess unmet needs in multiple sclerosis: tolerability and adherence. Multiple Sclerosis Journal. 18(7). 932–946. 105 indexed citations

19.

Fisher, Elizabeth, Eva Havrdová, Michael Hutchinson, et al.. (2006). The effects of natalizumab on brain atrophy and cognitive function: results from the AFFIRM study. 1 indexed citations

20.

Land, John M., et al.. (1999). Contribution of nitric oxide to exercise-induced hypotension in human sympathetic denervation. Clinical Autonomic Research. 9(5). 263–269. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact